MindBio Therapeutics Advances to Phase 2B Trial for Psychedelic Medicine in Major Depressive Disorder

MindBio Therapeutics has received the final go-ahead for a pioneering Phase 2B clinical trial, introducing a take-home microdosing regimen of MB22001, a proprietary version of LSD, for patients with Major Depressive Disorder (MDD). This advancement follows a Phase 2A trial where a significant remission rate was observed. The trial, set to begin on March 11, 2024, emphasizes MindBio's commitment to exploring innovative treatments for depression, a disorder affecting millions globally.

This double-blind, placebo-controlled trial will enroll 90 participants, evaluating the effects of MB22001 on depression over an eight-week period, with an additional eight-week extension ensuring comprehensive data collection. Previous trials have shown MB22001's potential in improving mood and sleep quality while fostering feelings of well-being without the severe side effects commonly associated with conventional antidepressants. MindBio's approach diverges from traditional high-dose psychedelics treatments, aiming for a scalable method that could revolutionize depression treatment accessibility and affordability.

Justin Hanka, CEO of MindBio, highlights the trial's significance in potentially disrupting the market for first-line depression treatments, emphasizing the scalability and lower side effects of microdosing MB22001. As MindBio gears up for this trial, the company continues to protect its intellectual property surrounding drug formulation and patient-specific treatment regimens, positioning itself as a frontrunner in the psychedelic medicine landscape.